Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jul 1:14:1369246.
doi: 10.3389/fonc.2024.1369246. eCollection 2024.

Exploring treatment decision-making in chronic myeloid leukemia in chronic phase

David Andorsky #  1 , Vamsi Kota #  2 , Kendra Sweet #  3
Affiliations
Review

Exploring treatment decision-making in chronic myeloid leukemia in chronic phase

David Andorsky et al. Front Oncol. .

Abstract

The introduction of tyrosine kinase inhibitors (TKIs) has transformed the treatment of chronic myeloid leukemia (CML). Each approved TKI has its own risk-benefit profile, and patients have choices across lines of therapy. Identifying the initial and subsequent treatment that will lead to the best possible outcome for individual patients is challenging. In this review, we summarize data for each approved TKI across lines of therapy in patients with CML in chronic phase, highlighting elements of each agent's safety and efficacy profile that may impact patient selection, and provide insights into individualized treatment sequencing decision-making aimed at optimizing patient outcomes.

Keywords: CML treatment; chronic phase; clinical decision-making; expert review; treatment selection; treatment sequencing.

PubMed Disclaimer

Conflict of interest statement

The authors declare the following potential conflicts of interest: DA received consulting fees and research funding from AbbVie and Celgene, and research funding from AstraZeneca and Novartis. KS received research funding from Jazz and Incyte and provides advisory board support/consulting for Gilead, Bristol Myers Squibb, Astellas, BerGenBio, Arog, Novartis, Curis, Pfizer, Mablytics, Daiichi Sankyo, Jazz, and Nkarta. VK received honorarium from Novartis and Pfizer. The authors declare that this study received funding from Novartis Pharmaceuticals Corporation. The funder had the following involvement in the study: provided financial support for medical editorial assistance.

Figures

Figure 1
Figure 1
Considerations for treatment selection and sequencing (2, 3). Various patient and disease factors play a role in treatment decision-making across lines of therapy. In addition, a patient’s experience on prior CML treatment, if applicable, along with access and cost considerations must be taken into account when treatment planning.
Figure 2
Figure 2
Treatment selection based on comorbidities (17, 70). Each TKI is associated with a unique AE profile which can help guide CML treatment decision-making, particularly in the case of patient comorbidities.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Hu Y, Li Q, Hou M, Peng J, Yang X, Xu S. Magnitude and temporal trend of the chronic myeloid leukemia: on the basis of the Global Burden of Disease study 2019. JCO Glob Oncol. (2021) 7:1429–41. doi: 10.1200/GO.21.00194 - DOI - PMC - PubMed
    1. Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. . European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. (2020) 34:966–84. doi: 10.1038/s41375-020-0776-2 - DOI - PMC - PubMed
    1. Shah NP, Bhatia R, Altman JK, et al. . Chronic myeloid leukemia, version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. (2024) 22:43–69. doi: 10.6004/jnccn.2024.0007 - DOI - PubMed
    1. Brümmendorf TH, Cortes JE, Milojkovic D, Gambacorti-Passerini C, Clark RE, le Coutre P, et al. . Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial. Leukemia. (2022) 36:1825–33. doi: 10.1038/s41375-022-01589-y - DOI - PMC - PubMed
    1. Cortes J, Saglio G, Kantarjian H, Baccarani M, Mayer J, Boque C, et al. . Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial. J Clin Oncol. (2016) 34:2333–40. doi: 10.1200/JCO.2015.64.8899 - DOI - PMC - PubMed

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by Novartis Pharmaceuticals Corporation. This review is sponsored and funded by Novartis Pharmaceuticals Corporation.

LinkOut - more resources